NCI Research Specialist Award (R50 Clinical Trial Not Allowed)

NCI Research Specialist Award (R50 Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI). Supports the development of independent cancer researchers who have demonstrated exceptional research capabilities and leadership potential.

Expired PAR-24-274: NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) This notice has expired. For NIH, in limited situations, applications may be accepted on a case-by-case basis for a short period after expiration to accommodate NIH late or continuous submission policies . Contact the eRA Service Desk for any submission issues.

Check the NIH Guide for active opportunities and notices. Department of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) Components of Participating Organizations National Cancer Institute ( NCI ) Funding Opportunity Title NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) R50 Research Specialist Award March 31, 2025 - This funding opportunity was updated to align with agency priorities.

Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission. September 9, 2024 - Notice of Pre-Application Webinar for PAR-24-274 - NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed). See Notice NOT-CA-24-105 .

April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084 . August 31, 2022 - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023.

See Notice NOT-OD-22-198 . August 5, 2022 - Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189 .

Funding Opportunity Number (FON) Companion Funding Opportunity See Section III. 3. Additional Information on Eligibility .

Assistance Listing Number(s) 93. 393, 93. 396, 93.

395, 93. 394, 93. 397, 93.

398, 93. 399 Funding Opportunity Purpose Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for the Research Specialist Award (R50) specifically for clinician scientists supporting NCI-funded clinical trials research.

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants.

These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others or other sources of support for cancer research career continuity.

Open Date (Earliest Submission Date) Letter of Intent Due Date(s) Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Required Application Instructions It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide , except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts ). Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced.

Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide , follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 1. Overview Information Part 2. Full Text of Announcement Section I.

Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV.

Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII.

Agency Contacts Section VIII. Other Information Part 2. Full Text of Announcement Section I.

Notice of Funding Opportunity Description Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for the Research Specialist Award in any area of NCI-funded clinical cancer research.

This NOFO is specifically for clinician scientists to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees, and other activities, but not serve as principal investigators of research project grants.

These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award is intended to provide stable support for clinician scientists at their institutions for significant leadership and exceptional participation in the NCI-sponsored clinical trials networks that conduct cancer treatment, prevention and control, and care delivery clinical trials.

NCI-sponsored clinical trials networks include but are not limited to the National Clinical Trials Network (NCTN), the NCI Community Oncology Research Program (NCORP), the Experimental Therapeutics Clinical Trials Network (ETCTN), and the Cancer Prevention Clinical Trials Network (CP-CTNet).

The Research Specialist Award is designed to encourage the development of a career path for cancer clinical trial investigators who provide leadership, participation, and scientific support for the NCI clinical trials networks at their institutions and within those networks.

This leadership includes the development of concepts and protocols for clinical trials, participation in scientific steering committees and network committees, and accrual to NCI-sponsored clinical trials.

The institutional activities may include the implementation of cancer clinical trials including participation in the review of safety data, monitoring the conduct and progress of open clinical trials, and serving on institutional review committees. These activities are necessary for the successful conduct of NCI-sponsored cancer clinical trials.

The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others or other sources of funding for cancer research career continuity.

The Research Specialist (Clinician Scientist) Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI-funded grants held by others or other sources of support for cancer research career continuity.

Over the past decade, cancer clinical trials have become more complex in trial design, have a greater number of regulatory issues to address and require significant effort from clinician investigators to review safety data, monitor the progress of multiple ongoing clinical trials, and respond to human subjects concerns that are both expected and unexpected.

These efforts are frequently not reimbursed and are neither funded in research project grants nor funded through the NCI clinical trials networks.

Typical research activities include service on institutional clinical research committees (institutional review boards, protocol review and monitoring for scientific prioritization, data safety, and management, disease- or modality-based disease groups, etc.), oversight of multiple clinical trials within a clinical trials office, service on national clinical trials committees (National Clinical Trials Network steering committees, etc.), developing new cancer clinical trials by writing and revising new protocols, recruiting patients to new and existing trials, and satisfying annual training in human subjects protection and regulatory compliance.

The need for individuals with the broad research expertise and clinical background required of clinician scientists is rapidly growing. Current sources of support for the research activities of clinician scientists are inadequate and compete against the growing demands of clinical duties and responsibilities.

The Research Specialist (Clinician Scientist) Award is intended to provide salary support for a sustained period of time and encourage the development of a stable career for exceptional clinical scientists who provide excellent leadership in the scientific development and implementation of NCI-sponsored clinical trials which are conducted through the NCI clinical trials networks.

The award is intended for clinician scientists with significant, relevant experience, who have shown clear evidence of productivity and research excellence in the implementation of NCI-funded clinical trials within their institution.

The proposed new research support is intended to provide salaries and sufficient autonomy so that individuals are not solely dependent on NCI-funded grants held by others or other sources of support for cancer research career continuity. As the PD/PI, Research Specialists would have the option, with prior NCI approval, to move to other research programs or institutions while maintaining funding from this award. See Section VIII.

Other Information for award authorities and regulations. Section II. Award Information Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.

Application Types Allowed The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO. Not Allowed: Only accepting applications that do not propose clinical trials.

Need help determining whether you are doing a clinical trial? Funds Available and Anticipated Number of Awards The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Application budgets may request the following two expenses in direct costs per year: salary support for the Research Specialist commensurate with their level of effort on NCI funded clinical trials with a minimum of 2. 4 and a maximum of 4.

8 person-months funded by this award; travel costs to attend research meetings/conferences: not to exceed $2,500 per year; and $2,000 per year for travel costs for the Principal Investigator to attend an annual meeting for Research Specialist (Clinician Scientist) Award recipients The total award project period may not exceed 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO. Section III.

Eligibility Information Higher Education Institutions Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education) Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education) For-Profit Organizations (Other than Small Businesses) City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Recognized) Eligible Agencies of the Federal Government U.S. Territory or Possession Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement , are not allowed. Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award.

All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.

3. 9. 2 Electronically Submitted Applications for additional information System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually .

The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.

Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM. gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants. gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.

Grants. gov – Applicants must have an active SAM registration in order to complete the Grants. gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role.

Obtaining an eRA Commons account can take up to 2 weeks. Eligible Individuals (Program Director/Principal Investigator) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide . Additional Eligibility Requirements: Eligible applicants will be clinician scientists who have a clinical degree (M. D.

, D. O. , D.

D. S. , D.

M. D. , O.

D. , D. C.

, PharmD. , N. D.

, D. V. M.)

, possess active licensure, and are actively practicing in an oncology clinical setting. Individuals with a Ph. D.

or other doctoral degree that have direct contact with patients or healthy subjects in clinical disciplines such as clinical psychology, nursing, clinical genetics, speech-language pathology, audiology, or rehabilitation are also eligible. At the time of application, the applicant cannot hold as a Principal Investigator current R01, P01, or other significant NIH funding (past funding does not affect eligibility).

Support from P50 Career Development awards, R03, R21, P30 funding, or national network funding will be allowed, as long as the total NCI support does not exceed 6 person-months. Future substantial independent NIH funding will require the awardee to forfeit the R50.

The applicant must have a record of involvement in NCI-funded cancer clinical trial-related activities and be engaged in the conduct of NCI-funded cancer clinical trials research at an academic medical center or at a community center that holds an NCORP award (primary site). At the time of submission, the Research Specialist must have been at the institution for at least the previous two years.

The Research Specialist must have a full-time position at the institution and be more than six years from initial faculty appointment at the time of the application submission deadline (including appointments held at other institutes). The Research Specialist must commit 2. 4 to 4.

8 person-months to NCI-funded clinical activities described in the Research Plan of the R50 application during the life of the award. The Research Specialist may engage in other duties as part of the remaining 9. 6 to 7.

2 person-month effort not covered by this award. The maximum funded effort allowed on all NCI grants, including the R50, will be capped at 6 person-months. The Research Specialist must have demonstrated professional accomplishments consonant with their career status and should have demonstrated cancer clinical research experience relevant to the NCI mission.

This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1. 2 Definition of Terms. 3.

Additional Information on Eligibility Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2. 3.

7. 4 Submission of Resubmission Application . This means that the NIH will not accept: A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.

A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application. An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2. 3.

9. 4 Similar, Essentially Identical, or Identical Applications ). Applications are limited to four per institution per receipt date including new (A0), resubmissions (A1) and renewal (T2); NCI-designated cancer center consortia are considered one institution.

NCI seeks a broad representation of institutions for this award mechanism and may take this into account when making funding decisions. Section IV. Application and Submission Information 1.

Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants. gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.

gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution. 2.

Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced.

Applications that are out of compliance with these instructions may be delayed or not accepted for review. All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed. Instructions for Application Submission The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO.

All instructions in the How to Apply - Application Guide must be followed. SF424(R&R) Project/Performance Site Locations All instructions in the How to Apply - Application Guide must be followed. SF424(R&R) Other Project Information All instructions in the How to Apply - Application Guide must be followed.

Include a table summarizing the clinical trials in which the applicant has played a significant role. Include specific funding source, National Clinical Trial ID, other protocol ID, applicant’s role, open and close dates, status, phase of trial, official title, targeted accrual (for the entire trial, and for the institution), and actual accrual by applicant.

SF424(R&R) Senior/Key Person Profile All instructions in the How to Apply - Application Guide must be followed. All instructions in the How to Apply - Application Guide must be followed. salary support for the Research Specialist commensurate with their level of effort devoted to the institution’s NCI funded clinical trials activities with a minimum of 2.

4 and a maximum of 4. 8 person-months effort supported by this award; travel costs to attend research meetings/conferences: not to exceed $2,500 per year; and $2,000 per year for travel costs for the Principal Investigator to attend an annual meeting for Research Specialist (Clinician Scientist) Award recipients All instructions in the How to Apply - Application Guide must be followed.

PHS 398 Cover Page Supplement All instructions in the How to Apply - Application Guide must be followed. All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: Specific Aims: DO NOT use. Specific Aims are not allowed.

Research Strategy: Applicants must upload the Research Strategy as a single attachment and the Research Strategy must be organized into the subsections identified below. Start each subsection of the document with the appropriate sub-heading. Sub-heading A .

Research Program(s) engaging the Research Specialist's activity/effort: Describe the scope of the clinical trials program with the level of effort in at least one of the NCI-sponsored clinical trials networks at the applicant’s institution. Sub-heading B.

Role of the Research Specialist in Research Program(s): Describe the particular activities of the Research Specialist (PD/PI) in NCI-sponsored clinical trials (examples enumerated above) and the need for the Research Specialist to ensure the success of the clinical trials program(s).

This section should explain how the Research Specialist’s qualifications, experience, productivity, accomplishments, and training are critical to achieving the scientific leadership in NCI-sponsored clinical trials networks and the leadership and participation in the successful implementation of the clinical trials at the applicant’s institution.

Describe the Research Specialist’s history of contributing to NCI-sponsored clinical trials networks at the institution by including the following: service and leadership of institutional clinical studies infrastructures, such as the clinical trials office, institutional review board, protocol review and monitoring board for scientific prioritization, and data safety and monitoring board(s); leadership of the institution’s disease- or modality-based groups; leadership in NCI clinical trial networks, such as National Clinical Trials Network disease/modality steering committees and other NCI-funded networks; serving as national or site PI of NCI-funded clinical trials; writing and revising of new clinical trials protocols; accruing patients to new or existing trials (as provided in the Other Attachment table); recruitment of underrepresented minority groups and women to clinical trials; Research Specialist's plans for meeting the objectives of the NCI-funded clinical trials research program at the institution over the next 5 years; the career goals of the Research Specialist with regard to continued support of NCI-funded clinical trial networks, and Sub-heading C.

Plans to Develop New Research Capabilities and/or Approaches: Describe the plans of the Research Specialist (PD/PI) to develop new research capabilities and/or approaches that will allow progress in the institution’s clinical trials program to improve efficiencies and address novel opportunities in the research programs. Plans to enhance recruitment of underrepresented minority groups and women to clinical trials are encouraged.

Letters of Support: Letters of support are required and applications that are missing letters of support will not be reviewed. Two types of Letters of Support are required for this application: I.

A letter of support from the institution, which must detail the following: a) The institution must document a strong, well-established cancer clinical trials program related to the Research Specialist's area of expertise, including a high-quality research environment with key faculty members and other investigators capable of productive collaboration with the Research Specialist.

b) Include a statement attesting to the Research Specialist's current level of effort in support of NCI-sponsored clinical trials, and a commitment to continue institutional support of effort should the R50 be awarded. II. At least three letters of recommendation from PDs/PIs who can attest to the Research Specialist's qualifications and contributions to NCI-funded clinical trials research.

Resource Sharing Plan : Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide . The following modifications also apply: Generally, Resource Sharing Plans are expected, but they are not applicable for this NOFO .

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: A Data Management and Sharing Plan is not applicable for this NOFO. Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply - Application Guide .

No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide , with the following additional instructions: If you answered “Yes” to the question “Are Human Subjects Involved?

” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record. Study Record: PHS Human Subjects and Clinical Trials Information All instructions in the How to Apply - Application Guide must be followed.

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply - Application Guide must be followed. PHS Assignment Request Form All instructions in the How to Apply - Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM) See Part 2. Section III.

1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants. gov 4. Submission Dates and Times Part I.

contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday , the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants. gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons , NIH’s electronic system for grants administration.

NIH and Grants. gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.

gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.

3. 9. 2 Electronically Submitted Applications .

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission. Information on the submission process and a definition of on-time submission are provided in the How to Apply – Application Guide . 5.

Intergovernmental Review (E. O. 12372) This initiative is not subject to intergovernmental review.

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement . Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7. 9.

1 Selected Items of Cost . It is anticipated that the terms of the award will include, but not be limited to the following: The requested salary support for the Research Specialist should be commensurate with the level of effort on the institution’s NCI-funded clinical trials. The Research Specialist is required to spend at least 2.

4 to a maximum of 4. 8 person-months of his/her effort NCI’s clinical trials with salary supported by this award, and with a maximum of 6. 0 person-months salary from all NCI grants.

The award will allow for travel funds but will not cover research expenses. Research expenses must be covered from other sources awarded to the Institution. The Research Specialist will have the option, with prior NCI approval, to move to another research program or institution.

The R50 must be relinquished if any substantial (not including R21, R03) NIH funding is subsequently obtained by the Research Specialist. Change of PD/PI (Research Specialist) will not be allowed on the R50. Attend an NCI-organized annual meeting for Research Specialist (Clinician Scientist) Award recipients.

7. Other Submission Requirements and Information Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide . Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide . If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form . Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply - Application Guide . See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review. Applications that are incomplete, and non-compliant will not be reviewed. Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award.

See Mandatory Disclosures, 2 CFR 200. 113 and NIH Grants Policy Statement Section 4. 1.

35 . Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at [email protected] . Post Submission Materials Applicants are required to follow the instructions for post-submission materials, as described in the policy Section V.

Application Review Information Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

For this particular announcement, note the following : The Research Specialist Award applications do not require preliminary data, specific aims, and/or a detailed research plan. Accordingly, reviewers will emphasize the following : Personal accomplishments of the Research Specialist, both individually and within the context of supporting the nominating institution’s clinical trials program(s).

The contributions of the Research Specialist to the cancer clinical trials program(s) of the institution to date and the NCI-sponsored clinical trials networks. The scope of NCI funded clinical trials at the institution, which the Research Specialist will support. The importance of the Research Specialist, as well as the commitment of the institution, to the proper and successful functioning of the institution’s clinical trials effort.

The institution’s level of accomplishments, research productivity, and adequacy